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Background
After a decade of combination antiretroviral therapy
(cART) availability, the epidemiological-clinical features
of HIV-associated pancreatic abnormalities changed over
time.
Methods
The frequency, risk factors, and clinical-therapeutic fea-
tures of pancreatic alterations were assessed in an observa-
tional, prospective case-control study involving 1,081
HIV-infected patients (pts) followed for >12 months.
Summary of results
166 pts with elevated and/or prolonged laboratory anom-
alies were focused on to assess pancreatic disease during
the cART era. The 435 pts (40.2%) who experienced >1
episode of pancreatic laboratory abnormality had a longer
duration of seropositivity and protease inhibitor (PI)
exposure, a more frequent immunodeficiency, AIDS diag-
nosis, chronic liver-biliary disease, and hypertriglyceri-
demia, while no relation was found with the duration-
type of administered nucleoside analogues, when com-
pared with the 646 controls, who never developed pancre-
atic anomalies. Among the mentioned 435 pts, elevated-
prolonged laboratory alterations eventually associated
with signs of organ involvement occurred in 166 cases
(38.2%), and were related to the administration of ddI,
d4T, 3TC, pentamidine, cotrimoxazole, or antimycobacte-
rial therapy, cytotoxic chemotherapy, substance-alcohol
abuse, opportunistic infections, chronic liver-biliary dis-
ease, a PI-based cART, and hypertriglyceridemia. How-
ever, no difference occurred between the 46 pts with
clinical-imaging evidence of pancreatic involvement and
the remaining 120 asymptomatic pts. Although recur-
rences of enzyme alterations involved 69.6% of pts, in
only 30.1% was a change of the antiretroviral-antimicro-
bial therapy needed. An acute but uncomplicated pancre-
atitis occurred in 9/46 symptomatic pts (19.6%). A 2–4-
week gabexate and/or octreotide administration (per-
formed in 79/166 cases: 47.6%), achieved a significant
laboratory, clinical, and imaging cure-improvement in
82.3% of cases, with a better success rate of combined
(gabexate+octreotide) vs. single (gabexate or ocreotide)
therapy. A significantly reduced tendency to disease recur-
rences, and a better tolerability of antiretroviral regimens,
were also found.
Conclusion
Epidemiological-pathogenetic studies are needed to assess
the trend of pancreatic abnormalities in the cART era, and
their relationship with continued antiretroviral-antimi-
crobial chemotherapy. This research field appears some-
what neglected, so that observational studies and
controlled trials are lacking. The indications to gabexate-
octreotide during HIV disease deserve investigation.
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